Fig. 1: Outcomes with VEN + HMA. | Blood Cancer Journal

Fig. 1: Outcomes with VEN + HMA.

From: Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents

Fig. 1

A Response outcomes. B Overall survival by type of marrow response (N = 65). Overall survival by FC-MRD (C) and NGS-MRD (D) status in patients with CR/CRi responses and evaluable MRD (n = 41 and n = 39, respectively). DoR duration of response, NE not estimable, ORR overall response rate. *ORR = CR + CRi + MLFS. †Of CR/CRi responses with evaluable MRD by the respective technique.

Back to article page